News
-
-
-
-
COMMUNIQUÉ DE PRESSE
First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Pentixapharm starts Phase I/II trial treating leukemia with Lu177-PentixaTher, a targeted radiotherapy. Study aims to expand treatment options for hematologic malignancies -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals
Pentixapharm welcomes CMS decision to enhance reimbursement for diagnostic radiopharmaceuticals, which could impact future streams for Ga68-PentixaFor and have broader market implications
